<unk>  inhibits a liver enzyme, CYP3A4, involved in the metabolism of many other commonly prescribed drugs. Taking<unk>  with other medications that are metabolized by CYP3A4 may lead to unexpected increases or decreases in drug levels. A few of the common interactions are listed below. Colchicine<unk>  has been observed to have a dangerous interaction with colchicine as the result of inhibition of CYP3A4 metabolism and P-glycoprotein transport. Combining these two drugs may lead to fatal colchicine toxicity, particularly in people with chronic kidney disease. Statins Taking<unk>  concurrently with certain statins (a<unk> ss of drugs used to reduce blood serum cholesterol levels) increases the risk of side effects, such as muscle aches and muscle break down (rhabdomyolysis). Calcium channel blockers Concurrent therapy with calcium channel blocker may increase risk of low blood pressure, kidney failure, and death, compared to pairing calcium channel blockers with azithromycin, a drug similar to<unk>  but without CYP3A4 inhibition. Administration of<unk>  in combination with verapamil have been observed to cause low blood pressure, low heart rate, and lactic acidosis. Carbamazepine<unk>  may double the level of carbamazepine in the body by reducing its clearance, which may lead to toxic symptoms of carbamazepine, such as double vision, loss of voluntary body movement, and nausea, as well as hyponatremia. HIV medications Depending on the combination of medications,<unk>  therapy could be contraindicated, require changing doses of some medications, or be acceptable without dose adjustments. For example,<unk>  may lead to decreased zidovudine concentrations.
Clarithromycin
Erythromycin
Cethromycin
Natamycin
Paromomycin
Clindamycin
Meropenem
Anisomycin